FDA's February 2026 Compounded GLP-1 Enforcement Announcement, Explained

What FDA announced on February 6, 2026

FDA Commissioner Martin A. Makary issued a press statement saying the agency intended to take “decisive steps” to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that companies mass-market as similar alternatives to FDA-approved drugs. The statement expressly named Hims & Hers and referred more broadly to other compounding pharmacies. FDA framed the action as consumer protection because the agency cannot verify the quality, safety, or efficacy of those unapproved products.

The second part of the announcement addressed direct-to-consumer promotion. FDA connected the escalation to warning letters sent in fall 2025 and said it would combat misleading advertising and marketing. It warned entities involved in manufacturing, distributing, or marketing unapproved compounded GLP-1 products that failure to correct violations could lead to legal action without further notice, expressly including seizure and injunction.

That distinction matters. An agency press release can provide clear notice of enforcement priorities and make continued conduct riskier, but it is not interchangeable with legislation or a final regulation. The strongest immediate message was directed at a business model: standardized compounded GLP-1 products promoted at scale as substitutes equivalent to approved medicines.

The four marketing claims FDA specifically rejected

FDA's wording was unusually concrete. In promotional materials, the agency said companies cannot make the following claims about non-FDA-approved compounded products:

• That the compounded product is a generic version of an FDA-approved drug.
• That the compounded product is the same as a drug approved by FDA.
• That the compounded product uses the same active ingredient as the FDA-approved drug.
• That the compounded product is clinically proven to produce results for the patient.

These are not merely semantic objections. A generic drug is itself reviewed and approved by FDA through an abbreviated new drug application and must satisfy legal standards that a compounded drug has not satisfied. Likewise, evidence supporting an approved semaglutide or tirzepatide product—including its formulation, manufacturing controls, container system, dose, route, and labeled use—does not establish that a separately compounded preparation has the same quality or will produce the same result.

A marketer can accurately disclose that a drug is compounded and can explain the individualized reason it was prescribed. What it cannot do is erase the regulatory and evidentiary difference through terms such as “generic,” “same,” or unsupported clinical-performance promises. Disclosures should be prominent, not contradicted by pricing tables, comparison graphics, testimonials, or other net impressions that present the compound as an approved product's interchangeable equivalent.

Why the shortage history is central

Federal law gives compounders more room when an approved drug appears on FDA's Drug Shortages List. In broad terms, shortage status can remove certain restrictions that otherwise prevent compounders from routinely making products that copy available approved drugs. That flexibility is temporary; it does not turn a compound into an FDA-approved product or excuse unrelated quality, labeling, prescription, or manufacturing violations.

FDA determined on December 19, 2024 that the shortage of tirzepatide injection products was resolved. It determined on February 21, 2025 that the shortage of semaglutide injection products was resolved. FDA allowed limited enforcement-discretion transition periods to reduce disruption, and lawsuits by the Outsourcing Facilities Association affected timing. For tirzepatide, the 503A transition ended after the district court denied preliminary relief on March 5, 2025, while the 503B period ran to March 19. For semaglutide, FDA reported that the 503A period had ended after an April 24 court ruling; the 503B period ran to May 22, 2025.

By February 2026, therefore, businesses could not rely on the former national shortages as a standing justification for mass production. The February 6 statement built on that already-changed legal environment; it did not create the shortage resolutions.

What the announcement means for 503A pharmacies

Section 503A generally covers traditional compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, for an identified individual patient based on a valid prescription. If all conditions are met, the preparation can qualify for exemptions from FDA approval, current good manufacturing practice requirements, and certain labeling directions. State pharmacy and medical-practice laws still apply.

Outside a shortage, section 503A restricts compounding a product that is essentially a copy of a commercially available drug regularly or in inordinate amounts. FDA's 2018 guidance says a product generally falls within that concept when it has the same API in the same, similar, or easily substitutable strength and the approved drug can be used by the prescribed route—unless the prescribing practitioner determines that a change produces a significant difference for the identified patient.

• Patient-specific means patient-specific. A prescription must be tied to an identified individual; a mass enrollment funnel is not a substitute for individualized clinical judgment.
• The prescriber—not promotional copy—makes the determination. If relying on a significant difference, the prescriber should identify the change and determine that it matters for that particular patient.
• Minor add-ons are not automatically enough. FDA has explained that combining semaglutide with another API such as vitamin B12 can still be an essentially copy when route and strengths are the same, similar, or easily substitutable and no documented patient-specific significant difference applies.
• The four-prescription policy is not permission for four copies. FDA guidance describes circumstances in which it generally does not intend to act when a compounder fills four or fewer prescriptions of a copied product in a calendar month. That is an enforcement policy, not a statutory safe harbor or proof that all other conditions are met.

For a 503A pharmacy, the practical effect of February 6 is increased scrutiny of both operations and downstream marketing. A pharmacy should be able to connect each preparation to a lawful prescription, substantiate any claimed significant difference, control who makes claims on its behalf, and avoid a standardized substitute program dressed up as customization. For a broader explanation of the patient-specific lane, see how 503A bulk-drug rules work.

What the announcement means for 503B outsourcing facilities

Section 503B outsourcing facilities are FDA-registered facilities that may compound larger batches without first receiving patient-specific prescriptions. They are subject to current good manufacturing practice requirements, FDA inspection, adverse-event reporting, and other conditions. Registration does not mean each compounded product is FDA approved.

Two separate constraints are important. First, a 503B facility generally may compound from bulk API only when the bulk substance appears on FDA's 503B Bulks List after a clinical-need determination, or when the drug compounded from that substance is on the Drug Shortages List at the relevant time. FDA's compounding update states that semaglutide and tirzepatide were on neither list. Second, section 503B restricts products that are essentially copies of one or more approved drugs; an identical or nearly identical product generally does not qualify unless the approved drug is in shortage.

This makes high-volume bulk-API production especially exposed after shortage resolution. An outsourcing facility cannot treat registration, a prescriber's preference, or market demand as a replacement for the statutory bulk-substance and copy conditions. It must also consider whether a non-identical variation is still essentially a copy under FDA's 503B guidance.

What telehealth and advertising companies should take from it

FDA did not announce a ban on telehealth. A licensed clinician may use telehealth when federal and state prescribing rules, professional standards, and the patient's circumstances allow it. The exposure arises when the platform's commercial design converts individualized prescribing into mass marketing of a standardized, unapproved substitute—or when its advertising makes the equivalence and efficacy claims FDA identified.

Responsibility is not confined to the pharmacy that mixes the drug. FDA's statement addressed entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products. A telehealth platform, lead generator, affiliate, prescriber group, or pharmacy may occupy different legal roles, but separating those roles by contract does not make misleading consumer-facing claims accurate.

• Audit landing pages, comparison charts, search ads, social posts, emails, affiliate scripts, and clinician-facing sales materials for the four claims FDA named.
• Clearly identify a compounded product as compounded and not FDA approved; do not display approved-brand evidence as if it validates the compounded preparation.
• Avoid menus that present token formulation changes as automatic “personalization” for every customer.
• Ensure clinical intake, prescription decisions, significant-difference documentation, dispensing, and interstate practice comply with the laws applicable to each participant.

What consumers and patients should know

The announcement does not tell a patient to stop a prescribed medicine abruptly, and this article cannot determine whether a specific compounded drug is appropriate. It does mean patients should not assume that a lower-cost product described beside an approved brand has been reviewed as a generic or shown to be interchangeable. Compounded drugs can meet genuine clinical needs, but FDA does not verify their safety, effectiveness, or quality before they are marketed.

• Ask whether the dispensed product is FDA approved or compounded, and identify the dispensing pharmacy on the label.
• Ask the prescriber why a compounded preparation is needed for you and what significant difference it provides over an available approved product.
• Confirm the exact drug, concentration, units, dose, and measuring device. Do not infer dosing from an approved pen when using a compounded vial.
• Be cautious when a seller uses “generic,” “same ingredient,” “same as,” or “clinically proven” to equate its compound with an approved GLP-1 drug.
• Report suspected quality problems or adverse events through FDA MedWatch, and contact a health professional promptly for medical concerns.

Patients seeking background on the class can read how GLP-1 signaling works, the semaglutide overview, and the tirzepatide overview. Those educational pages do not replace prescribing advice.

Why this was not an outright ban—and what remains permitted

Calling the February 6 action a “ban” overstates the document. FDA did not say no GLP-1 medicine could ever be compounded. It announced intended restrictions and enforcement against mass-marketed unapproved products and misleading claims. Lawful compounding remains possible when the facts meet every condition of the relevant pathway.

Nor did the announcement change the status of FDA-approved products or prohibit clinicians from prescribing an approved medicine off label when medically appropriate. “Off-label” use of an approved drug and use of an unapproved compounded preparation are legally and evidentially different: the former uses a product FDA has reviewed; the latter does not.